Piramal Pharma FY25 Revenue Rises 12% to ₹9,151 Cr; EBITDA Up 15%

Piramal Pharma Annual Report for FY25: 

Financial Performance & Profitability

• Revenue from Operations reached ₹ 9,151 Cr in FY25, up 12% YoY (₹ 8,171 Cr in FY24), with Q4 revenues growing 8% year-on-year
• EBITDA grew 15% YoY in FY25 to ₹ 1,580 Cr and 8% in Q4, maintaining a strong 17% margin .
• PAT before exceptional items was ₹ 91 Cr for FY25 (13% growth), while PAT after adjustments surged to ₹ 91 Cr from ₹ 18 Cr—a fivefold increase
• Net Debt / EBITDA ratio improved significantly, closing at 2.7×, down from 5.6× in FY23

Business Segment Highlights

CDMO (Contract Development & Manufacturing Organization)

• Accounted for 60%+ of revenue, growing 15% YoY to ₹ 5,447 Cr in FY25 and 8% in Q4
• Innovation-linked work rose to 54% of CDMO business (from 50% in FY24), with on‑patent commercial manufacturing revenue soaring over 50% to US$ 179 Mn
• Differentiated offerings grew 28% YoY, making up 49% of CDMO revenues. Quality compliance exceptional — cleared 36 inspections and 165 audits with zero major observations

Complex Hospital Generics (CHG)

• Delivered 6% YoY growth, totalling ₹ 2,633 Cr in FY25. Inhalational anaesthetics (Sevoflurane, Baclofen) maintained #1 US market share (44% & 75% respectively)
• Capacity expansions in India (Dahej, Digwal) completed and commissioned on schedule—positioned to tap ~US$ 400 Mn global Sevoflurane opportunity
• Launched Neoatricon® formulation for infants—approved in EU/UK via partner BrePco Pharma

Consumer Healthcare (ICH)

• Grew 11% YoY in FY25 to ₹ 1,093 Cr; Q4 saw 15% YoY growth
• Power brands grew ~20 % YoY, comprising ~49% of ICH portfolio; excluding regulated price‑controlled i-range brands, growth jumps to ~26%
• Launched 21 new products and 31 new SKUs in FY25; e‑commerce grew 39% YoY, now accounts for ~21% of ICH sales across 20+ platforms
• Debut media campaign with Yami Gautam for Little’s brand category

Sustainability & ESG Focus

• Released its FY24 Sustainability Report titled "Building Resilience for a Sustainable Tomorrow", aligned with GRI, SASB, UNGC frameworks
• Targeting 42% reduction in Scope 1 & 2 GHG emissions and 25% in Scope 3 by FY2030 (base year: FY22) under SBTi guidance
• Achieved 29% increase in renewable energy use, converted coal-fired boiler at Digwal to biomass (cutting ~24,000 tCO₂e or 80% of non-hazardous waste while planting 2,440 saplings

Strategic Direction & FY2030 Aspirations

• Firmly on path to achieve US$ 2 billion in revenue with ≈25% EBITDA margins, high‑teens ROCE, and 1× Net Debt/EBITDA by FY2030
• Capex underway: US$ 80 Mn Lexingto
  n expansion to double sterile fill–finish capacity by FY27; capacity scale‑up in India to serve global market demand